Segment Information - Schedule of CODM expense categories (Detail) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Segment Reporting Information [Line Items] | |||||||||
| License and service revenue: | $ 0 | $ 6,359 | $ 0 | ||||||
| Research and Development Expense [Abstract] | |||||||||
| Total research and development | $ 2,840 | $ 898 | $ 4,500 | $ 1,408 | 3,056 | 3,577 | 8,598 | ||
| General and administrative | 1,610 | 684 | 3,746 | 1,396 | 3,382 | 5,250 | 8,690 | ||
| Total operating expenses | 4,450 | 1,582 | 8,246 | 2,804 | 6,438 | 8,827 | 17,288 | ||
| Loss from operations | (4,450) | (1,582) | (8,246) | (2,804) | (6,438) | (2,468) | (17,288) | ||
| Total other expense (income), net | (52) | (309) | (10) | (796) | 443 | (675) | 234 | ||
| Net loss | (4,502) | $ (3,754) | (1,891) | $ (1,709) | (8,256) | (3,600) | (5,995) | (3,143) | (17,054) |
| Segments Member | |||||||||
| Segment Reporting Information [Line Items] | |||||||||
| License and service revenue: | 0 | 6,359 | 0 | ||||||
| Research and Development Expense [Abstract] | |||||||||
| Clinical and manufacturing | 1,812 | 184 | 2,484 | 373 | 718 | 1,193 | 2,577 | ||
| Other research and development | 1,028 | 714 | 2,016 | 1,035 | 2,338 | 2,384 | 6,021 | ||
| Total research and development | 2,840 | 898 | 4,500 | 1,408 | 3,056 | 3,577 | 8,598 | ||
| General and administrative | 1,610 | 684 | 3,746 | 1,396 | 3,382 | 5,250 | 8,690 | ||
| Total operating expenses | 6,438 | 8,827 | 17,288 | ||||||
| Loss from operations | (4,450) | (1,582) | (8,246) | (2,804) | (6,438) | (2,468) | (17,288) | ||
| Other (income) expense, net | 52 | 309 | 10 | 796 | (443) | 675 | (234) | ||
| Total other expense (income), net | 52 | 309 | 10 | 796 | (443) | 675 | (234) | ||
| Net loss | $ (4,502) | $ (1,891) | $ (8,256) | $ (3,600) | $ (5,995) | $ (3,143) | $ (17,054) | ||
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|